Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687020 · ClinicalTrials.gov registry record · Phase 4
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
A Phase 4 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
- Active
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 5
- Study locations
NCT04687020 is a Phase 4 study of Duchenne Muscular Dystrophy that is active but no longer recruiting, run by NS Pharma. The registered enrollment target is 9 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04687020, a Phase 4 study of Duchenne Muscular Dystrophy, is active but no longer recruiting, sponsored by NS Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 5
- Study locations
Study Summary
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
Conditions Studied
Interventions
- DRUG Viltolarsen
Study Locations (5)
California
- UC Davis - Sacramento
Illinois
- Lurie Children's Hospital - Chicago
North Carolina
- Duke University Medical Center - Durham
Virginia
- Children's Hospital of Richmond at VCU - Richmond
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2032-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04687020
The ClinicalTrials.gov registry entry for NCT04687020 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (98% lower). The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Viltolarsen is the first listed.
NCT04687020 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04687020 about?
NCT04687020 is a clinical study titled "Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)". The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
What is the current status of trial NCT04687020?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2021-06-10. Estimated completion is 2032-10.
What conditions does trial NCT04687020 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT04687020?
The interventions under investigation include: Viltolarsen (DRUG).
Who is sponsoring clinical trial NCT04687020?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04687020 being conducted?
This trial has 5 study locations across California, Illinois, North Carolina, Virginia, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
The Duchenne Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.